17 innovation-"https:"-"https:"-"https:"-"https:"-"https:"-"https:"-"https:" positions at Amsterdam UMC
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
. You will join a young and dynamic research team with an open and creative working environment. We encourage new ideas and innovative research projects and offer opportunities to develop your scientific
-
. As the model develops, you will: enhance and stabilise the presence of osteoclasts in the system and establish reliable osteoblast–osteoclast communication within the chip; design and refine culture
-
You will collaborate with doctoral candidates, postdoctoral researchers, analysts, and clinical researchers conducting patient studies. We encourage active participation in the design and execution
-
patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical
-
Lung cancer and mesothelioma remain among the deadliest cancers worldwide, highlighting the need for more effective and targeted therapies. Our research focuses on developing innovative treatments
-
patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical
-
this project, you will develop innovative image analysis methods to improve image quality and enable advanced quantitative analyses of ^89Zr-immunoPET data, including radiomics and artificial intelligence
-
priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical translation, patient engagement, and
-
patient-informed treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical
-
treatment priorities. To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical translation, patient